由中国药学会、美国巴特尔(Battelle)科学技术研究院和中国生化制药工业协会共同发起的首届中国国际生物制药研讨会12月7日~11日在北京召开。会议期间,来自美国、欧盟、中东和亚太地区的中小型生物医药企业、政府和科研机构的专家学者近200人,围绕疫苗、抗体和基因治疗药物所涉及的科研、生产、监管、法规与知识产权保护、国际贸易等话题,通过大会报告、壁报、企业展示等方式,进行了广泛、深入、富有成效的交流。
http://www.cpa.org.cn/icbps/icbps.htm
中国国际生物制药研讨会会议议程(最新)
ICBPS Program
Thursday December 7
1500-1830
Registration
1830-1900
Meeting of Session Chairs, Co-Chairs and Presenters
1900-2100
The Welcome Party
Friday December 8
0730-0830
Registration Continued
0830-0900
The ICBPS Opening
Chair: Ms. Shaoli Li, General Secretary,CPA
Co-Chair: David Robinsom,Vice President,Biotherapeutics,Battelle
Mr.Chang Wenzuo,Director-General,Department of International Cooperation,SFDA
Prof.Wang Junzhi, Deputy Dirctor, NICPBP
Mr.Zheng Xiaoyu, President,Chinese Pharmaceutical Association
Prof.Zhou Haijun, Honorary President of CPA
Mr. Zhu Jinning, Director of International Affairs, China Association of Sciense and Technology
Prof. Wang Lifeng,General Manager, China National Biotec Group(CNBC)
Lieutenant General,David Poythress, The Adjutant General for the State of Georgia, US
Dr. Erna Tresnaningsih,Director Biomedical and Pharmacy R&D Center, Ministry of Health, Indonesia
0900-1000
Session 1(Each presentation of this session should be finished in 30 minutes)
Chair: Prof. Wang Junzhi
Co-Chairs: Dr. Anna Johnson-Winegar Prof. Liu Baokui
S1-1
• A Special Report, "New Emerging Issues with H5N1 Avian Flu in Indonesia"
Dr. Erna Tresnaningsih, Director Biomedical and Pharmacy R&D Center, Ministry of Health, Indonesia
S1-2
• The international importance of furthering dialog, coordination/cooperation in critical areas such as biopharmaceuticals and pharmaceuticals.
Lieutenant General David Poythress, The Adjutant General for the State of Georgia, US
1000-1020
Coffee Break
1020-1200
Session 1 Continued
S1-3
Measles vaccine immunogenicity after co-administration with live attenuated Japanese encephalitis vaccine shows equivalence to that of measles vaccine given alone
Gatchalian(Liu Shaoxiang),China
S1-4
• Partnerships: From Applied Science to Commercialization
Steven Bice, US
S1-5
• Antibody-Based Biopharmaceuticals in China
Prof. Zhi-nan Chen, China
1200-1330
Lunch
1330-1510
Session 2 (Each presentation of this session should be finished in 20 minutes, leave 5 minutes for Q&A)
Chair: David Moore
Co-Chairs: Dr. Elizabeth Poythress Prof. Xie Guilin
S2-1
•Current Status of Conjugate Vaccine Development in China
Guilin Xie,China
S2-2
• The Need for Innovation in the Development of New or Improved Vaccines
Luc Aujame, France
S2-3
• Acambis Clinical Development of Programme for ChimeriVax-JE
Dr. Karen L. McCarthy, UK
S2-4
• The Development of Freeze-dried Live Chickenpox Vaccine with the Virus Strain Beijing 84-7
Dr.Xu Lifeng,China
1510-1530
Coffee Break
1530-1700
Session 2 Continued
S2-5
• Trend of the Third Revision of the Chinese Patent Law
Dr. Jia Chen,Zhao Chen, China
S2-6
• An Overview of the Drug Sector within the Saudi Food and Drug Authority with Emphasis on Biologicals
Dr. Mohammed N. Al-Ahdal, Saudi Arabia
S2-7
• Licensing of Medical Products Requires Using Alternate Approaches on Efficacy Demonstration when Traditional Human Clinical Trials are not Possible: US FDA Animal Rule and Biological Safety Considerations
Dr. James Estep, US
S2-8
• The Clinical Trial for a New Drug
Dr. Wu Gang, China
Saturday December 9
0830-1000
Session 3(Each presentation of this session should be finished in 20 minutes, leave 5 minutes for Q&A)
Chair: Dr.David Trudil
Co-Chairs: Michael Langford Prof.Wang Youchun-NICPBP
S3-1
• A Novel Polyepitope Malaria Vaccine Randomly Constructed with Epitope Shuffling
Prof. Heng Wang, China
S3-2
• The Adenovirus-Based Therapeutic Vaccine for Hepatitis B
Prof. Joe Zhou, China
S3-3
• Use of Bacteriophage Lytic Enzymes for Effective Decontamination by Killing Antibiotic Resistant and other Pathogenic Bacteria
Dr. David Trudil, US
S3-4
• A Study on the Process for the preparation of Proteosome Adjuvant of Vaccine and their Adjuvant Effect on Plague Vaccine Containing Recombinant F1-V Protein by Intranasally Immunization
Dr. Wu Xiu-fang, China
1000-1020
Coffee Break
1020-1210
Session 3 Continued
1020-1120
• Poster Session (3 minute oral presentation for 20 selected posters)
1120-1210
• Poster Viewing
1210-1330
Lunch
1330-1510
Session 4 (Each presentation of this session should be finished in 20 minutes, leave 5 minutes for Q&A)
Chair: Nicholas Hamilton
Co-Chairs: Dr.Peng Zhaihui Dr. Aileen Marty
S4-1
• Emerging Infections in the Asian Part of Russia
Prof. Sergey Netesov, Russia
S4-2
• Traditional Knowledge and Indigenous Biotechnology in China
Dr. Susan Finston, US
S4-3
• Key Factors in Growing European Biotechnology
Dr. Ben Prickril, France
S4-4
• Corporate Overview: Emergent Biosolutions, US
1510-1530
Coffee Break
1530-1730
Session 4 Continued
S4-5
• Anti-Microbial Drug Loaded Mucoadhesive Nanparticles for Opthalmic Delivery
Dharmendra Jain, India
S4-6
• CD6-Targeted Immunotherapy: Back and Forward from Basic Research to the Clinical Setting
Dr. Enrique Montero, China
S4-7
• The Mechanism, Safety and Efficacy of Gendicine®
Dr. Zhaohui Peng, China
S4-8
• Correlation of Disulfide Bond Conformation to Hormonal Activity of Oxytocin
Prof. Anthony Tu, US
S4-9
• Diphtheria, Tetanus and Acellular Pertussis (DTaP) Vaccine in CNBC Wuhan
Xiaoming Yang,China
1830-1900
Depart Hotel Crowne Plaza for Symposium Dinner
Dinner at the Huguang Club - a very special venue, during dinner you can enjoying opera
Sunday, December 10
0830-1000
Session 5 (Each presentation of this session should be finished in 20 minutes, leave 5 minutes for Q&A)
Chair: Dr.Xie Liangzhi
Co-Chairs: John Woodall Prof. Zhu Xun
S5-1
• Bridging the Gap Between Basic Research and Final Product Approval
Dr. Anna Johnson-Winegar, US
S5-2
The Biopharmaceutical Market in Brazil
Dr Jack WOODALL, Brazil
S5-3
The Present and the Future of Tumor Vaccine Development:A Historical Review and Perspectives
Dr. Zhuxun ,China
S5-4
• The Many Faces of H5N1 - Applying an Understanding of Pathology and Pathogenesis towards the Development of Novel Biopharmaceuticals
Prof. Aileen Marty, US
1000-1020
Coffee Break
1020-1200
Session 5 Continued
S5-5
• State-of-the-Art Platform for Rapid Biological Product Development
Dr. Liangzhi Xie, China
S5-6
• Genetic Factors and Environmental Impact as a Determinant of Interindividual Varibility in CYP2B6
Dr. A. Alrohaimi, Saudi Arabia
S5-7
• Alternate Treatment in Biological Crisis and Implications for the Pharmaceutical Industry
Dr. Florin Paul. Romania
S5-8
• RNA Interference in Drug Target Identification and Validation
Dr. Cao Yueqiong, China
1200-1300
Lunch
1300
Buses leave for Great Wall tour. Please be on time. Only resisted through ASA can join the tour.
Monday December 11
0830-1000
Session 6 Each presentation of this session should be finished in 20 minutes, leave 5 minutes for Q&A)
Chair: Sergey Netesov
Co-Chairs: Prof. Shen Jun Dr.Jeffrey Allen
S6-1
• Bacteriophages - Alternate to Antibiotics Against Multi-Drug Resistant Bacterial Infections: From Former Soviet Experience to Worldwide Perspectives
Dr. Mzia Kutateladze, Republic of Georgia
S6-2
• Non-replicating Adenovirus-Vectored Avian Influenza Vaccine
Dr. Kent Van Kampen, US
S6-3
• Development and Optimization of a Recombinant Adenovirus Vectors Production Process
Dr. Zhao-Lie Chen, China
S6-4
•Establishment of Technique Systems of Expression Recombinant Proteins in Ginseng Cell
Sheng Jun,China
1000-1020
Coffee Break
1020-1200
Session 6 Continued
• Summary from each Session Chair or Co-Chair
*5 to 7 minutes for each Session
• A Farewell for all ICBPS members and their guests
1200-1300
Lunch
1300-
Buses leave for Tour to Industry
壁报名单
Author
Title of Poster
Poster No.
Bin Wang
The adjuvant effects of co-stimulatory molecules on cellular and memory responses to HBsAg DNA vaccination
B1
Cao Yueqiong
RNA Interference in Drug Target Identification and Validation
C1
Chen Ze (ONE)
Humoral Immune Response and Protection against the Lethal Influenza Virus by Immunization with Inactivated Influenza Vaccine in Diabetic Mice
C2
Chen Ze (TWO)
The Virological, Epidemiological and Clinical Features of Influenza A, B, C Virus and Influenza Vaccine
C3
He Tai-ping
Expression of Human-Mouse Chimeric Antibody against TNF-Α in CHO Cells
H1
He Tai-ping
Development of A Recombinant Cell Line Expressing High-Level Antibody and Characterization of Its Antibody
H2
Hui Yao
Vaccine Research on Stomatology
H3
J.F. Babcock
Target Protein Production in CHO-K1 Cells Cultivated in A Protein Hydrolysate-Supplemented Medium.
J1
Jaeseung YOON
Third Generation Vaccine and Therapeutic Antobody for Hepatitis B Virus
J2
Kawa F. Dizaye
The Positive Inotropic and Diuretic Effects of Procyanidine Isolated from Crataegus Azarolus
K1
L.Pozdnyakova,
Biotechnological Approaches for the Infectious Diseases Evaluationand Prevention Optimizations in the Ukraine
L1
LI Zhenping
Preparation of Purified Inactivated Japanese Encephalitis Vaccine by the Bioreactor
L2
Lin Jiang
Study on the Antigenicity, Immunogenicity and Protective Effects Possessed by Recombinant Hepatitis E Vaccine
L3
Liu Fanglei
Comparation of Immunogenicity in Mice of Different Neisseria Meningococcal Serogroup A Polysaccharide-Protein Conjugate Vaccines
L4
Liu Hongyan
The Expression of HPV16/18L1 in the Piehia Pastoris and Preparation of the Antibodies
L5
Pan Shunan
Verification of Elisa Method on Detecting Residual Bovine Serum Contents in Viral Vaccines
P1
Peng Xiangbing
Cloning and Expression of Hcv C-Ns3 Chimeric Gene by Soe-Pcr
P2
Qu Aidong
The Study on the Site-Mutants of Diphtheria Toxin and Its Expression in E.Coli
Q1
Reza Afshari
Defining Illicit Pharmaceutical Market in 21st Century
R1
Samad Radjai
Successful Replacement of Serum by Plant Protein Hydrolysates in Cell Culture Media
S1
Shi Wei
Secreting Expression of Thymusin Alpha 1 in Pichia System
S2
Tan Changyao
Preparation and Immunogenicity of A Picha Pastoris-Derived Hepatitis B Vaccine Containing Pres1, Pres2 And S Epitopes
T1
Tian Shenghe
Apoptosis Effect of Recombinant Strail on Human Leukaemia K562 Cell Line
T2
Vincent GANNE
Montanide ISA 720 and 51: A New Generation of Water in Oil Emulsions as Adjuvants for Human Vaccines
V1
Wang Hui
Study on Production Technology and Quality Ensure of Vero Cell-Derived Inactivated Japanese Encephalitis Vaccine
W1
Wei-fen Li
Oral Vaccine Delivery System of Lactococcus Lactis and Its Improvements
W2
Weixing Chen
Breakthrough Technology for Large-Scale Protein Production with Transient Transfection Using CHO Suspension Cultures
W3
Willy W.L. Hong
RNA Silencing to Dihydrofolate Reductase Genes for Stable Producer Chinese Hamster Ovary Cells in Gene Amplification Process by A Stepwise Methotrexate Selection
W4
Xu Fanhong
Construction and Expression of Human G-CSF and FLT3 Ligand Fusion Protein in E.coli
X1
Xu Xiangtian
The Advance on Study and Applied on the Hepatitis B Therapeutic Vaccines
X2
Ying Lian-fang
Fermentation and Purification for the Recombinant Of HEV
Y1
Zhang Guoqiang
Study and Confirmation of Quantitative ELISA Kit for the Detection of Ovalbumin
Z1
Zhang Nan
Preparation and Characterization of Monoclonal Antibodies against Sars-Associated Coronavirus
Z2
Zhang Ping
Preparation of a Conjugate Vaccine Composed of Pneumococcus Type 14 Capsular Polysaccharide Bound to TT
Z3
Zhang Zhenlong
Construction,Expression and Activity Analysis of Recombinant Human Ciliary Neurotrophic Factor Derivative
Z4
Zhang Zhizhou
Modernization of Chinese Medicine is Facing Threat in Systems Biology Era
Z5
Zhao Hong
The Efficiency of the Mouse Model for Evaluating Toxin-Neutralization in Vitro and Protection in Vivo of Anti-Tetanus Human Monoclonal Antibodies
Z6
Zheng Xinxiong
Safety and Efficacy Test of Freeze-Drying Purified Human Rabies Vaccine Manufactured by Wibp
Z7
前言
为了促进我国生物医药技术的发展,认真分析与国际同行间存在的优势与差距,切实加强国际间的交流与合作,提高对生物医药市场的开发、引导和监督管理能力,由中国药学会、美国巴特尔科学技术研究院和中国生化制药工业协会共同发起的首届中国国际生物制药研讨会将在北京召开。此次会议我们将组织来自美国、欧盟、中东和亚太地区的中小型生物医药企业、与生物医药相关的工业、政府和科研机构的专家学者参加会议,围绕疫苗、抗体和基因治疗药物所涉及的科研、生产、监管、法规与知识产权保护、国际贸易等话题,通过大会报告、壁报交流、企业展示等方式,本着认真、求实、学习、解决问题的态度,为与会代表搭建一个进行广泛、深入、富有成效的交流平台,使国内参会者全面了解全球生物医药技术与市场的发展动态并为国内生物医药企业创造全球合作机会。
国际执行委员会
Dr. Mason Soule, Battelle, USA
刘春光,中国药学会,中国
Dr. Richard M. Price, ASA, USA
Dr. Steve Bice, Battelle, USA
Dr. Mick Garstang, Acambis plc, UK
论文评审委员会
Dr. David Robinson, Battelle, USA
Dr. Barbara B. S. Price,ASA, USA
Dr. James Estep, Battelle, USA
Dr. Mohammed Al-Ahdal, SFDA, Saudi Arabia
Dr. Ben Prickril, BioVision, France
Prof.Jack Woodall, University of Rio De Janeiro and founder ProMed, Brazil
北京生物制品研究所副所长,沈心亮,研究员
中国军事医学科学院生物工程研究所副所长,曹诚,研究员
中国药品生物制品检定所,王佑春,研究员
中国生化制药工业协会常务副会长,王福清,高级工程师

RSS订阅






